Ultragenyx Pharma (RARE) Misses Q2 EPS by 16c, beats revenue

Ultragenyx Pharma (NASDAQ: RARE) reported Q2 EPS of ($2.25), $0.16 worse than the analyst estimate of ($2.09). Revenue for the quarter came in at $108.3 million versus the consensus estimate of $107.1 million.

For earnings history and earnings-related data on Ultragenyx Pharma (RARE) click here.

You May Also Be Interested In

• 'Ocean of opportunity': Wolfe initiates SpaceX at Buy ahead of historic IPO
• RH (RH) Tops Q1 EPS by 12c
• 51Talk Online Education Group (COE) Reports Q1 EPS of $0.00